OSCR
Oscar Health, Inc.
OSCR has the edge over USPH overall, supported by stronger fundamentals and stronger modeled upside.
USPH
U.S. Physical Therapy, Inc.
USPH has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
USPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
USPH's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
USPH PE Valuation
USPH has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over USPH on the outlook, with more favorable profitability expectations.
USPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for USPH, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus USPH up 38%.
USPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.22 | +35% |
| Q3 2023 | $1.72 | -42% |
| Q2 2023 | $1.93 | -34% |
| Q1 2023 | $2.16 | -25% |
| Q4 2022 | $2.25 | -6.6% |
| Q3 2022 | $2.98 | +26% |
| Q2 2022 | $2.92 | +26% |
| Q1 2022 | $2.87 | +15% |
| Q4 2021 | $2.41 | -2.8% |
USPH earned $2.38 per share over the past year, up 38% from the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over USPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
USPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.6M | +13% |
| Q2 2026 | $214.1M | +8.5% |
| Q1 2026 | $198.3M | +7.9% |
| Q4 2025 | $202.7M | +12% |
| Q3 2025 | $197.1M | +17% |
| Q2 2025 | $197.3M | +18% |
| Q1 2025 | $183.8M | +18% |
| Q4 2024 | $180.4M | +17% |
USPH's revenue has grown year over year for 22 quarters in a row: $223M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -1.6 points |
| Q2 2026 | 10% | -2.4 points |
| Q1 2026 | 6.3% | -4.4 points |
| Q4 2025 | 8.3% | +0.2 points |
| Q3 2025 | 13% | +4.1 points |
| Q2 2025 | 13% | +0.9 points |
| Q1 2025 | 11% | +1.5 points |
| Q4 2024 | 8.1% | +8.6 points |
USPH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over USPH on cash flow, with more consistent year-over-year improvement.
USPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +32% |
| Q2 2026 | $29M | -8.2% |
| Q1 2026 | -$1.6M | +$5.7M |
| Q4 2025 | $21M | +24% |
| Q3 2025 | $15.6M | -20% |
| Q2 2025 | $31.6M | +19% |
| Q1 2025 | -$7.3M | -381% |
| Q4 2024 | $16.9M | -31% |
USPH generated $69M in free cash flow over the past year, up 21% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
USPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -142K shares |
| 1 year | -1.8% | -276K shares |
| 3 years | -0.4% | -59K shares |
| 5 years | +16% | +2M shares |
| Available history | +17% | +2.2M shares |
USPH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over USPH on leverage, with a lower net debt burden relative to earnings.
USPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.0x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
USPH's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
USPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.9 | Overbought |
| Stochastic | 86.8 | Overbought |
USPH's weekly RSI is 73 (overbought) and its Stochastic is 87 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
USPH PE vs Healthcare Sector
| Metric | USPH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
USPH has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
USPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.9 | 11% above |
| 20 week MA | $82.1 | 20% above |
| 50 week MA | $78.1 | 26% above |
| 100 week MA | $79.1 | 25% above |
| 200 week MA | $88.4 | 12% above |
USPH has climbed back above all five of its weekly moving averages, and it's now 12% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over USPH on returns for 2026, with the stronger performance.
USPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $114.0 | $120.9 | +6% |
| 2021 | $120.9 | $95.7 | -21% |
| 2022 | $95.7 | $81.4 | -15% |
| 2023 | $81.4 | $93.1 | +14% |
| 2024 | $93.1 | $90.9 | -2.4% |
| 2025 | $90.9 | $81.0 | -11% |
| 2026 YTD | $81.0 | $98.6 | +22% |
USPH has finished lower in four of the last six years. It's up 22% so far in 2026.